Next Article in Journal
ATP- and Polyphosphate-Dependent Glucokinases from Aerobic Methanotrophs
Previous Article in Journal
Phylogenomic Analyses of Bradyrhizobium Reveal Uneven Distribution of the Lateral and Subpolar Flagellar Systems, Which Extends to Rhizobiales
Previous Article in Special Issue
Potential Role for the Gut Microbiota in Modulating Host Circadian Rhythms and Metabolic Health
Article Menu

Export Article

Open AccessArticle
Microorganisms 2019, 7(2), 51; https://doi.org/10.3390/microorganisms7020051

Effects of Bifidobacterium bifidum in Mice Infected with Citrobacter rodentium

1
Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada
2
Joannah and Brian Lawson Centre for Child Nutrition, Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada
*
Author to whom correspondence should be addressed.
Received: 12 December 2018 / Revised: 7 February 2019 / Accepted: 11 February 2019 / Published: 14 February 2019
(This article belongs to the Special Issue Gastrointestinal Microbiota Impacts Human Health and Disease)
Full-Text   |   PDF [3537 KB, uploaded 14 February 2019]   |  

Abstract

In vitro and in vivo studies suggest that selected Bifidobacterium bifidum strains sustain intestinal homeostasis. This study aimed to examine whether the administration of B. bifidum MIMBb75 (BB75) attenuates Citrobacter rodentium infection, a murine model for enteric infection and inflammatory bowel disease in humans. C57Bl6/J mice were randomized to receive BB75 daily starting before or after C. rodentium infection. BB75 load and infection kinetics were monitored. On day 10 post-infection (p.i.), histological parameters of the large intestine were assessed. Barrier integrity was evaluated by pathogen translocation to secondary organs and in vivo permeability test. Fecal C. rodentium load peaked at 1010 CFU/g at day 10 p.i., with clearance at day 24 p.i., regardless of probiotic treatment. BB75 administration resulted in 107 cells/g of feces with no effect of timing of administration. BB75 treatment did not attenuate C. rodentium-induced crypt hyperplasia nor inflammation. C. rodentium and BB75 can co-exist in the gut with no mutual displacement. However, BB75 cannot counteract C. rodentium pathology. Our findings provide insight for the understanding of probiotics behavior and their clinical relevance in intestinal inflammation. View Full-Text
Keywords: Bifidobacterium bifidum MIMBb75; Citrobacter rodentium; inflammatory bowel disease (IBD); EHEC infection; colitis; probiotics Bifidobacterium bifidum MIMBb75; Citrobacter rodentium; inflammatory bowel disease (IBD); EHEC infection; colitis; probiotics
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Wen, B.; Taibi, A.; Villa, C.R.; Lee, S.-H.; Sagaidak, S.; Comelli, E.M. Effects of Bifidobacterium bifidum in Mice Infected with Citrobacter rodentium. Microorganisms 2019, 7, 51.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Microorganisms EISSN 2076-2607 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top